Please login to the form below

Not currently logged in

Oliver Rausch to lead translational research partnership efforts at NIHR

Has experience at UCB, GSK and Cellzome

NIHR Dr Oliver RauschDr Oliver Rausch has been appointed programme director of the UK's National Institute for Health Research translational research partnerships.

As part of the NIHR's Office for Clinical Research Infrastructure (NOCRI), the partnerships was created to support collaboration between industry, the NHS and academia in early and exploratory research for products with the potential to have a direct effect on improving healthcare.

Efforts currently cover two areas, inflammatory respiratory disease and joint and related inflammatory diseases, both of which shall be overseen by Dr Rausch.

He brings industry experience to the role having spent the past 15 years working at pharma companies across Europe.

Most recently, he was VP biology at Cellzome, and he has further experience as director, new chemical entities biology at UCB and as an investigator with GlaxoSmithKline (GSK).

Prior to joining the industry, Dr Rausch was a postdoctoral scientist at the Institute of Cancer Research in London.

“Oliver's appointment will strengthen the development of the Partnerships and underpins NOCRI's commitment to clear and streamlined access to the UK's world-leading clinical research infrastructure,” said Mark Samuels, managing director of NOCRI.

14th September 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...